| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion
|
Mulder, S. F.
|
|
2014
|
9 |
4 |
p. 331-338
|
artikel
|
| 2 |
Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer
|
Mitrović, Olivera
|
|
2013
|
9 |
4 |
p. 367-379
|
artikel
|
| 3 |
Curcumin and lung cancer—a review
|
Mehta, Hiren J.
|
|
2014
|
9 |
4 |
p. 295-310
|
artikel
|
| 4 |
EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients
|
Honma, Helen N.
|
|
2014
|
9 |
4 |
p. 389-394
|
artikel
|
| 5 |
ESMO 2014: new trends in precision medicine
|
Morere, J. F.
|
|
2014
|
9 |
4 |
p. 293-294
|
artikel
|
| 6 |
Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment
|
Kozakowski, Nicolas
|
|
2013
|
9 |
4 |
p. 359-366
|
artikel
|
| 7 |
Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis
|
Li, Zhijun
|
|
2014
|
9 |
4 |
p. 381-388
|
artikel
|
| 8 |
Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients
|
Zhang, Minghui
|
|
2013
|
9 |
4 |
p. 349-357
|
artikel
|
| 9 |
Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme
|
Mansour, Joshua
|
|
2014
|
9 |
4 |
p. 395-398
|
artikel
|
| 10 |
Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a Phase II study
|
Balaña, Carmen
|
|
2014
|
9 |
4 |
p. 321-329
|
artikel
|
| 11 |
Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort
|
Fourrier-Réglat, Annie
|
|
2013
|
9 |
4 |
p. 311-319
|
artikel
|
| 12 |
Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT
|
Boers-Sonderen, Marye J.
|
|
2014
|
9 |
4 |
p. 339-347
|
artikel
|
Tijdschrift beschrijving